Please provide your email address to receive an email when new articles are posted on . SGLT2 and GLP-1 agents were linked to lower risk of kidney-related outcomes for adults with type 2 diabetes and ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors ...

In a real-world study of patients aged 60 years or older with diabetes, SGLT2 inhibitor users experienced a significantly slower decline in estimated glomerular filtration rate compared with DPP4 ...

Please provide your email address to receive an email when new articles are posted on . “DPP-IV inhibitors and SGLT2 inhibitors are commonly used second-line antidiabetic medications,” Ching-Lung ...

This transcript has been edited for clarity. Matthew Sparks, MD: Hi. I'm Dr Matthew Sparks and welcome to Medscape's InDiscussion series on chronic kidney disease. This is episode 1, and today we'll ...

Credit: Getty Images Evidence in favor of SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists for treating patients with diabetic kidney disease is growing. In combination with ...

Adults with type 2 diabetes treated with an SGLT2 inhibitor had roughly a third fewer episodes of acute kidney injury (AKI) compared with matched people with type 2 diabetes treated with a DPP4 ...

Data shows sodium-glucose cotransporter-2 (SGLT2) inhibitors are efficacious and can be used in almost all common kidney diagnoses, explained William G. Herrington, MD, MA, MBBS, Nuffield Department ...

Observational study data suggest that SGLT2 inhibitor use reduces risks for kidney and cardiovascular events even in patients with an eGFR less than 15 mL/min/1.73 m2 who have type 2 diabetes.

SGLT-2 inhibitors, a type of diabetes medicine, decreased cardiovascular risk among adults with chronic kidney disease, according to late-breaking research presented today at the American Heart ...